9966.HK
Price:
$11.22
Market Cap:
$9.83B
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast can...[Read more]
Industry
Biotechnology
IPO Date
2019-12-12
Stock Exchange
HKSE
Ticker
9966.HK
According to Alphamab Oncology’s latest financial reports and current stock price. The company's current ROE is 12.63%. This represents a change of -18625.20% compared to the average of -0.07% of the last 4 quarters.
The mean historical ROE of Alphamab Oncology over the last ten years is -36.25%. The current 12.63% ROE has changed -134.84% with respect to the historical average. Over the past ten years (40 quarters), 9966.HK's ROE was at its highest in in the December 2018 quarter at 36.66%. The ROE was at its lowest in in the December 2017 quarter at -380.32%.
Average
-36.25%
Median
-19.86%
Minimum
-246.37%
Maximum
56.12%
Discovering the peaks and valleys of Alphamab Oncology ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 17.18%
Maximum Annual ROE = 56.12%
Minimum Annual Increase = -172.10%
Minimum Annual ROE = -246.37%
| Year | ROE | Change |
|---|---|---|
| 2024 | 9.08% | -172.10% |
| 2023 | -12.59% | -39.77% |
| 2022 | -20.91% | -5.17% |
| 2021 | -22.05% | 17.18% |
| 2020 | -18.82% | -45.41% |
| 2019 | -34.48% | -161.44% |
| 2018 | 56.12% | -122.78% |
The current ROE of Alphamab Oncology (9966.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-8.14%
5-year avg
-13.06%
10-year avg
-36.25%
Alphamab Oncology’s ROE is less than HBM Holdings Limited (18.28%), less than Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (15.32%), less than Shanghai Haohai Biological Technology Co., Ltd. (6.84%), less than Nanjing Leads Biolabs Co Ltd (0%), less than Abbisko Cayman Limited (7.17%), greater than Lepu Biopharma Co., Ltd. (-24.47%), greater than CARsgen Therapeutics Holdings Limited (-39.53%), less than Beijing Chunlizhengda Medical Instruments Co., Ltd. (8.81%), greater than CStone Pharmaceuticals (-71.29%), greater than Ascletis Pharma Inc. (-13.49%),
| Company | ROE | Market cap |
|---|---|---|
| 18.28% | $10.38B | |
| 15.32% | $11.30B | |
| 6.84% | $10.28B | |
| 0% | $9.85B | |
| 7.17% | $8.74B | |
| -24.47% | $9.80B | |
| -39.53% | $8.39B | |
| 8.81% | $9.16B | |
| -71.29% | $8.53B | |
| -13.49% | $12.05B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alphamab Oncology using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alphamab Oncology or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Alphamab Oncology's ROE?
How is the ROE calculated for Alphamab Oncology (9966.HK)?
What is the highest ROE for Alphamab Oncology (9966.HK)?
What is the 3-year average ROE for Alphamab Oncology (9966.HK)?
What is the 5-year average ROE for Alphamab Oncology (9966.HK)?
How does the current ROE for Alphamab Oncology (9966.HK) compare to its historical average?